U.S. Cell Therapy Raw Materials Market To Reach $9.37 Billion By 2033

U.S. Cell Therapy Raw Materials Market Growth & Trends

The U.S. cell therapy raw materials market size is anticipated to reach USD 9.37 billion by 2033 and is projected to grow at a CAGR of 18.42% from 2025 to 2033, according to a new report by Grand View Research, Inc. The market of U.S. cell therapy raw material is experiencing robust growth, driven by the expanding pipeline of cell and gene therapies, rising clinical trial activity, and increasing regulatory approvals. Growing demand for GMP-grade, high-quality raw materials, such as media, supplements, and viral vectors, is fueling investment in advanced biomanufacturing. Moreover, the presence of well-established CDMOs, supportive government initiatives, and strategic collaborations between raw material suppliers and therapy developers are further accelerating market expansion across clinical and commercial production settings.

Growing clinical trial activity in the U.S. is playing a pivotal role in driving demand for high-quality raw materials used in cell therapy development. With the U.S. leading the global landscape in cell and gene therapy trials, especially across early-phase research, has upsurged the need for GMP-grade inputs, such as basal media, growth factors, plasmid DNA, and viral vectors. These components are essential to ensure the safety, consistency, and scalability of therapeutic candidates, particularly in clinical settings where product quality is non-negotiable.

As more biopharmaceutical companies and academic institutions advance novel therapies into the pipeline, pilot-scale and personalized manufacturing requirements have intensified. This trend is prompting raw material suppliers to innovate and offer customizable solutions to meet evolving clinical demands. Furthermore, strategic alliances between therapy developers and suppliers are streamlining material access, ensuring consistency in quality and regulatory compliance. The growing clinical trial footprint is thus creating a ripple effect across the raw material supply chain, accelerating both innovation and infrastructure development.

However, one of the key restraints in the U.S. cell therapy raw materials industry is the high manufacturing complexity and associated costs of producing GMP-grade materials. Raw materials such as cytokines, growth factors, and viral vectors require highly controlled environments, strict regulatory compliance, and sophisticated production technologies, all of which significantly increase operational expenses.

 Request a free sample copy or view report summary: U.S. Cell Therapy Raw Materials Market Report

U.S. Cell Therapy Raw Materials Market Report Highlights

• The cell culture supplements segment led the market with the largest revenue share of 25.35% in 2024. This dominance is attributed to their critical role in optimizing cell growth, viability, and functionality across various therapy types. The increasing demand for specialized, serum-free, and GMP-grade supplements further supports their widespread adoption in both clinical and commercial manufacturing. However, the media segment is anticipated to grow at the fastest CAGR of 19.68% over the forecast period.

• By end-use, the biopharmaceutical & pharmaceutical companies segment accounted for the largest market revenue share in 2024. This is due to their extensive involvement in clinical trials and commercial-scale manufacturing. Their focus on developing advanced therapies drives consistent demand for high-quality raw materials. The CROs & CMOs segment is anticipated to grow at the fastest CAGR over the forecast period.

U.S. Cell Therapy Raw Materials Market Segmentation

Grand View Research has segmented the U.S. cell therapy raw materials market based on the product, and end use:

U.S. Cell Therapy Raw Materials Product Outlook (Revenue, USD Million, 2021 - 2033)

• Media

• Sera

• Cell Culture Supplements

• Antibodies

• Reagents & Buffers

• Others

U.S. Cell Therapy Raw Materials End Use Outlook (Revenue, USD Million, 2021 - 2033)

• Biopharmaceutical & Pharmaceutical Companies

• CROs & CMOs

• Others

List of Key Players in U.S. Cell Therapy Raw Materials Market

• Thermo Fisher Scientific Inc.

• Merck KGaA

• Danaher

• Sartorius Stedim Biotech

• Actylis.

• ACROBiosystems

• STEMCELL Technologies.

• Grifols, S.A.

• Charles River Laboratories

• RoosterBio, Inc.

• PromoCell GmbH